Abstract: The present invention provides conjugates of disorazoles and their derivatives with cell-binding molecules, such as peptides, proteins, hormones, blood proteins and antibodies. The present invention further provides novel disorazole derivatives and processes of manufacturing such conjugates and disorazole derivatives. These compounds can be used as medicaments for the treatment of physiological and/or pathophysiological conditions in mammals, in particular for the treatment of various tumors.
Type:
Grant
Filed:
September 6, 2007
Date of Patent:
June 22, 2010
Assignee:
Aeterna Zentaris GmbH
Inventors:
Eckhard Guenther, Olaf Schaefer, Michael Teifel, Klaus Paulini
Abstract: The invention relates to pharmaceutical compositions suitable for parenteral administration comprising, peptides in the form of acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salts in dissolved or dispersed form and at least one of the acids for forming the salts in free acid form.
Type:
Grant
Filed:
May 18, 2001
Date of Patent:
May 18, 2010
Assignee:
AEterna Zentaris GmbH
Inventors:
Horst Bauer, Michael Damm, Werner Sarlikiotis
Abstract: A method for preventing aggregation of an LHRH antagonist in a pharmaceutical composition. The method comprises combining the LHRH antagonist in the form of an acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salt and at least one of the acids for forming the salts in free acid form.
Type:
Grant
Filed:
January 4, 2005
Date of Patent:
April 13, 2010
Assignee:
AEterna Zentaris GmbH
Inventors:
Horst Bauer, Michael Damm, Werner Sarlikiotis
Abstract: The invention relates to disorazoles of the general formula I, which are employed as medicaments, preferably for the treatment of oncoses, in particular in the case of pharmaceutical resistance to other active compounds and in the case of metastasizing carcinoma. The possible uses are not restricted to oncoses.
Type:
Application
Filed:
April 7, 2009
Publication date:
December 17, 2009
Applicant:
AEterna Zentaris GmbH
Inventors:
Herbert Irschik, Rolf Jansen, Florenz Sasse, Silke Baasner, Peter Schmidt, Eckhard Gunther
Abstract: A novel lyophilizate and method of preparation as well as the use of the lyophilizate to treat female infertility and for gonad protection. Cetrorelix is dissolved in acetic acid 30% v/v, the solution is transferred to water and freeze dried.
Type:
Grant
Filed:
January 24, 2005
Date of Patent:
October 20, 2009
Assignee:
AEterna Zentaris GmbH
Inventors:
Jürgen Engel, Burkhard Wichert, Dieter Sauerbier, Gudrun Sauerbier, legal representative, Thomas Reissmann
Abstract: The invention provides 1,2,4-triazole compounds, compositions containing those compounds, methods of treating diseases and/or disorders with those compounds and processes of manufacturing 1,2,4-triazole compounds.
Type:
Application
Filed:
March 17, 2009
Publication date:
September 24, 2009
Applicants:
AETERNA ZENTARIS GmbH, CENTRE NAT DE LA RECHERCHE SCIENTIFIQUE, University of Montpellier I, University of Montpellier II
Inventors:
Jean-Alain Fehrentz, Mathieu Bibian, Aline Moulin, Jean Martinez
Abstract: The invention relates to methods of treatment or prophylaxis of physiological and/or pathological conditions with at least one LHRH antagonist, in particular at least one peptidomimetic LHRH antagonistsuch that the at least one LHRH antagonist is administered in a dose, which does not cause chemical (hormonal) castration.
Abstract: The present invention provides novel tetrahydrocarbazole compounds according to formula (I) as ligands of G-protein coupled receptors (GPCR) which are useful in the treatment and/or prophylaxis of physiological and/or pathological conditions in mammals mediated by GPCR or of physiological and/or pathological conditions which can be treated by modulation of these receptors.
Type:
Application
Filed:
April 25, 2008
Publication date:
July 2, 2009
Applicant:
AETERNA ZENTARIS GmbH
Inventors:
Tilmann Schuster, Klaus Paulini, Peter Schmidt, Silke Baasner, Emmanuel Polymeropoulos, Eckhard Guenther, Michael Teifel
Abstract: The present invention provides at least one LHRH antagonist for the treatment or prophylaxis of at least one lower urinary tract symptom in mammals which is to be administered in an intermediate dose, which does not cause chemical (hormonal) castration.
Abstract: The present invention provides triazole derivatives according to formula (I) as ligands of G-protein coupled receptors (GPCR), which are useful for the study of and/or the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, which are mediated by GPCR.
Type:
Application
Filed:
February 14, 2008
Publication date:
February 12, 2009
Applicant:
AETERNA ZENTARIS GmbH
Inventors:
Daniel Perrissoud, Huy Ong, Mukandila Mulumba, Christian Jossart, Yves Lachance
Abstract: The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to 12 weeks. According to another aspect of the present invention, the short term LH-RH treatment is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
Type:
Application
Filed:
April 7, 2008
Publication date:
October 16, 2008
Applicant:
Aeterna Zentaris GmbH
Inventors:
Hilde RIETHMULLER-WINZEN, Jurgen Engel, Ricardo Felberbaum, Klaus Diedrich, Kupker Wolfgang
Abstract: A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural levelS thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg, preferably 2 mg-6 mg. In multiple dosing-posology, LH-RH antagonist can be administered subcutaneously in an amount in the range of 0.1 to 0.5 mg of LH-RH antagonist/day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addition rec.
Type:
Grant
Filed:
September 15, 2003
Date of Patent:
July 1, 2008
Assignee:
AEterna Zentaris GmbH
Inventors:
Philippe Bouchard, Rene Frydman, Paul Devroey, Klaus Diedrich, Jurgen Engel
Abstract: The invention relates to novel indole derivatives of the general formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.
Abstract: The invention relates to novel indole derivatives of the general formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.
Abstract: The invention relates to novel indole derivatives of the general formula 1, to their preparation and to their use as medicaments, in particular for treating tumors
Abstract: The present invention provides conjugates of disorazoles and their derivatives with cell-binding molecules, such as peptides, proteins, hormones, blood proteins and antibodies. The present invention further provides novel disorazole derivatives and processes of manufacturing such conjugates and disorazole derivatives. These compounds can be used as medicaments for the treatment of physiological and/or pathophysiological conditions in mammals, in particular for the treatment of various tumors.
Type:
Application
Filed:
September 6, 2007
Publication date:
April 17, 2008
Applicant:
AETERNA ZENTARIS GmbH
Inventors:
Eckhard Guenther, Olaf Schaefer, Michael Teifel, Klaus Paulini
Abstract: The present invention provides novel anthracene compounds according to the formulae (I) and (II) and also selected anthracene compound compounds. The present invention furthermore provides a process for preparing such anthracene compounds. Also provided are pharmaceutical formulations comprising these anthracene compounds. The anthracene compounds provided are particularly suitable for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions which can be treated by inhibiting tubulin polymerization and/or by inhibiting microtubuli-based motor proteins, in particular various tumor disorders.
Type:
Application
Filed:
August 3, 2007
Publication date:
February 28, 2008
Applicant:
AETERNA ZENTARIS GmbH
Inventors:
Matthias Gerlach, Eckhard Gunther, Peter Schmidt, Helge Prinz, Konrad Bohm, Eberhard Unger
Abstract: LHRH analogues and LHRH antagonists for use in the treatment or prophylaxis of hormone-dependent cancers, in particular prostate cancer, prostate carcinoma and/or advanced prostate carcinoma, by administering an initial dose of an LHRH analogue over a first period sufficient to effect hormonal castration, then administering a maintenance dose of an LHRH antagonist over a second period, the dose being insufficient to achieve and/or maintain hormonal castration.
Abstract: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general Formula I, their preparation and use as medicaments, in particular for the treatment of malignant and other disorders based on pathological cell proliferations.